Improving targeted radiation therapy for prostate cancer using personalized dosimetry and biomarkers
Enhancing radioligand therapy for prostate cancer with biomarker and dosimetry guided personalization
This study is looking to improve treatment for advanced prostate cancer by customizing radiation therapy based on each patient's unique needs, using special imaging to determine the best dose for their tumors while keeping side effects low.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10857881 on NIH RePORTER |
What this research studies
This research focuses on enhancing radioligand therapy for metastatic castrate resistant prostate cancer by personalizing treatment based on individual patient characteristics. It utilizes advanced imaging techniques to estimate the absorbed dose of radiation to tumors and critical organs, allowing for tailored dosing strategies. By analyzing pre-therapy imaging and adjusting the dosage for the first treatment cycle, the goal is to maximize the effectiveness of the therapy while minimizing potential side effects. Patients will be monitored closely to assess the impact of these personalized approaches on treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic castrate resistant prostate cancer who are eligible for radioligand therapy.
Not a fit: Patients with early-stage prostate cancer or those not eligible for radioligand therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer radiation treatments for prostate cancer patients.
How similar studies have performed: Previous research has shown promising results with personalized approaches in radiation therapy, suggesting potential for success in this novel application.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Dewaraja, Yuni K — University of Michigan at Ann Arbor
- Study coordinator: Dewaraja, Yuni K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.